Home » Market News » DirectorsTalk Highlights » Breast cancer DNA ‘barcoding’ programme set to expand
Evgen Pharma Plc

Breast cancer DNA ‘barcoding’ programme set to expand

A pioneering breast cancer programme that scans DNA ‘barcodes’ for tailored treatments is set to benefit thousands of patients.

Cancer Research UK has awarded more than £1 million to the Personalised Breast Cancer Programme (PBCP) following the successful pilot phase.

Further funding from The Mark Foundation for Cancer Research, a US-based philanthropic organisation, will help the programme reach 2,000 patients.

Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The company is carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. Evgen Pharma’s objective is to become the leading company in the development of pharmaceuticals that activate the antioxidant response element, Nrf2.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.